News archive search
Search stored headlines and summaries, then narrow the results by company, country, sector, industry, source or date.
Active search
simplywall.st Earnings
Search results
External headlines link to their original source. Market context comes from stored weekly company data, not from an opinion about the article.
Quantinno Capital Management LP has acquired a new position in STAAR Surgical Company, purchasing 59,302 shares valued at approximately $1.11 million. This makes Quantinno Capital Management LP a 0.12% stakeholder in the company, which has seen its revenue increase by 111.1% year-over-year in the …
Staar Surgical Co (STAA) shares surged 3.4% to $26.19, with a GF Score of 80/100, indicating strong overall performance. The stock is considered "Modestly Undervalued" by GuruFocus, with a potential upside of 21.8% from its current price, although its high P/E ratio and lack …
A group of investment entities associated with Eli Samaha, collectively known as the Madison Avenue group, has reported a beneficial ownership of 8.4% in STAAR Surgical Company (STAA) as of June 30, 2026. This stake represents 4,175,748 shares of Common Stock out of 49,788,495 …
UBS has adjusted its price target for STAAR Surgical Company (STAA) to $19, down from $20, while maintaining a Sell rating on the stock. This update reflects the analyst's current outlook on the medical equipment company. The article also notes recent company activities including …
STAAR Surgical reported a strong Q2 2026, returning to profit with $8.1 million in net income and $93.5 million in sales, largely driven by significant growth in China. Despite these positive results, the stock price barely moved, reflecting investor concerns about the company's heavy …
Jefferies has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $28 from $29, while maintaining a Hold rating, following the company's second-quarter 2026 results. STAAR Surgical reported Q2 revenue of $93.5 million, beating consensus estimates, with strong China sales, but missed earnings per …
STAAR Surgical reported record first-half revenue, driven by the successful launch of EVO Plus in China, which helped gain market share despite a challenging refractive market. The company is strategically shifting to a platform approach, with plans for new product development and a transition …
STAAR Surgical Company's average 12-month price target has been reduced to $28.89 from $29.33, according to estimates from 9 analysts. This updated target suggests a potential upside of approximately 14% based on the August 12 closing price. The consensus rating for the stock remains …
Piper Sandler reiterated a Neutral rating on STAAR Surgical (NASDAQ:STAA) with a $33.00 price target, following the company's second-quarter results. While STAAR Surgical's China business exceeded expectations, generating $52.3 million in revenue, the company missed revenue expectations in other key regions like the United …
Wedbush has lowered its price target for STAAR Surgical (NASDAQ:STAA) to $37.00 from $40.00 but maintained an "outperform" rating, indicating a potential upside of 45.61%. Despite this, analyst sentiment is mixed, with an average "hold" rating and a consensus price target of $26.61. The …
STAAR Surgical reported a 111% year-over-year jump in Q2 2026 net sales to $93.5 million, with China contributing over half of this revenue at $52.3 million. The company saw significant profitability improvements, including a gross margin increase to 74.5% and net income of $8.1 …
STAAR Surgical (NASDAQ: STAA) announced significant Q2 2026 financial results, with net sales reaching $93.5 million, an 111 percent increase year-over-year. This surge was primarily driven by the Chinese market, which accounted for over half of the quarterly revenue. The company also reported improvements …
Key Points Interested in STAAR Surgical Company? Here are five stocks we like better. STAAR Surgical reported a strong second quarter: Net sales more than doubled to $93.5 million, while the company returned to profitability with $8.1 million in net income and $20 million …
Staar Surgical (STAA) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.21 per share. This compares to a loss of $0.07 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents …
STAAR Surgical (NASDAQ:STAA) reported strong Q2 CY2026 results, with revenue up 111% year-on-year to $93.54 million, exceeding analyst expectations, and GAAP EPS of $0.16, beating estimates by 12.6%. Despite these positive numbers, the stock dropped 8% immediately after the announcement. The company's operating margin …
STAAR Surgical Company (STAA) reported its Q2 revenue of $93.5 million, surpassing FactSet's estimate of $90.6 million. This financial update indicates a positive performance for the medical equipment company during the second quarter. The article provides a brief overview of the company's recent earnings.
Defender Capital LLC. reduced its stake in STAAR Surgical Company (NASDAQ:STAA) by 33.1% in the second quarter, now holding 431,187 shares valued at $12.37 million, which represents 4% of its portfolio. STAAR Surgical reported strong Q2 earnings, beating analyst expectations with EPS of $0.10 …
STAAR Surgical (STAA) is set to report its Q2 earnings this Wednesday after market hours. Analysts expect a 104% year-on-year revenue growth, a significant reversal from the previous year's decline. Despite past revenue misses, analysts have reconfirmed their estimates, though STAA's share price has …
Sharemaestro market context Price below Trend Line 52 weeks +1.4%STAAR Surgical (STAA) recently formalized Warren Foust's role as President, CEO, and director, with Deborah Andrews becoming Executive Vice President and CFO, solidifying a leadership structure that was previously interim. This move is seen as reinforcing investor confidence by consolidating control under a leader …
This article announces the filing of a Form 8K by STAAR Surgical Company on August 6th. The brief piece from Investing.com indicates that the Form 8K is publicly available for review. The publication also provides various market data and other news headlines.
STAAR Surgical has appointed Warren Foust as President and Chief Executive Officer, effective August 4, 2026. Foust previously served as Interim Co-CEO, President, and COO, and his compensation package includes a base salary of $730,000, a significant cash bonus target, and substantial equity grants …
STAAR Surgical (STAA) recently appointed Warren Foust as its new CEO, drawing investor attention despite recent share price declines. While analysts set a consensus price target of $29.67, indicating the stock is undervalued, key risks such as reliance on a single distributor in China …
Staar Surgical (STAA) has been upgraded to a Zacks Rank #1 (Strong Buy), indicating an upward trend in its earnings estimates. This upgrade suggests positivity about its earnings outlook, which could lead to increased buying pressure and a rise in its stock price. The …
STAAR Surgical has appointed Warren Foust as its permanent CEO, following a period of leadership uncertainty after the collapse of Alcon's $1.6 billion takeover bid. Foust, who previously served as interim co-CEO and president, will continue as president, while Deborah Andrews resumes her role …
Search by ticker symbol or company name and select a result to open its chart.